High-Dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors.

Trial Profile

High-Dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Docetaxel; Etoposide; Filgrastim; Gemcitabine; Ifosfamide; Melphalan; Mesna
  • Indications Germ cell and embryonal neoplasms
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results (n=69) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 17 Jun 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 17 Feb 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top